Johnson & Johnson

News

NICE declines to look again at depression drug Spravato

Johnson & Johnson has slammed a decision by NICE not to carry out a new appraisal of its antidepressant Spravato, claiming it has “grave concern” about access to new mental health treat

News

J&J shares data on would-be blockbuster antidepressant

Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial

News

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill

News

FDA sets date for Sarclisa in first-line multiple myeloma

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi

R&D

This week in clinical trials: 20th to 24th May

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.

News

J&J reels in bispecific specialist Proteologix in $850m deal

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc

NICE declines to look again at depression drug Spravato

J&J shares data on would-be blockbuster antidepressant

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal

FDA sets date for Sarclisa in first-line multiple myeloma

This week in clinical trials: 20th to 24th May

J&J reels in bispecific specialist Proteologix in $850m deal

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Johnson & Johnson

Editor's Picks